Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avirol C
- Development stage
- Unknown
- Lead developer
- Nika Farm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Avirol C** is an orally administered, fixed-dose hard-gelatin capsule marketed by Nika Pharm in Uzbekistan for etiotropic and symptomatic treatment of influenza, acute respiratory viral infections, and fever associated with viral respiratory-tract infection in adults and children older than 12 years. It contains paracetamol, rimantadine hydrochloride, ascorbic acid, loratadine, rutin, and calcium supplied as calcium carbonate. ([nikapharm.uz](https://nikapharm.uz/en/product/avirol-c))
- Brand names
- Avirol CАвирол С
02
Targets
Ascorbate-dependent monooxygenase and hydroxylaseHerpesvirus DNA polymeraseHSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))POLA1 (DNA polymerase alpha)HRH1 (Histamine H1 Receptor)CHRM2 (M2)
Beyond the preview
Go deeper on Avirol C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avirol C.